Given the reduction in both CV outcomes and associated, all-cause mortality, are the LDL-C thresholds currently recommended by the AHA and ESC low enough, and what are the implications for PCSK9-mediated CV risk reduction?

Given the reduction in both CV outcomes and associated, all-cause mortality, are the LDL-C thresholds currently recommended by the AHA and ESC low enough, and what are the implications for PCSK9-mediated CV risk reduction?

CLICK HERE FOR CME CREDIT

Given the reduction in both CV outcomes and associated, all-cause mortality, are the LDL-C thresholds currently recommended by the AHA and ESC low enough, and what are the implications for PCSK9-mediated CV risk reduction?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical and Preventive Cardiologist's Perspective

Presenter

Sergio Fazio, MD

Sergio Fazio, MD

Director, Center for Preventive Cardiology Professor of Medicine Division of Cardiovascular Medicine School of Medicine Oregon Health Sciences University (OHSU) Portland, OR